Ebene News – United States – DEADLINE FOR QS SHAREHOLDERS: Bernstein Liebhard LLP Reminds Investors of Deadline to File Principal Plaintiff’s Motion in Securities Class Action Against QuantumScape Corporation

NEW YORK, February 17, 2021 (GLOBE NEWSWIRE) – Bernstein Liebhard, a nationally recognized investor rights law firm, reminds investors of deadline to file lead plaintiff in a securities class action lawsuit that was filed on behalf of investors who purchased or acquired securities of QuantumScape Corporation (“QuantumScape” or the “Company”) (NYSE: QS) from November 27, 2020 to December 31, 2020 (the “Recourse Period”) Lawsuit in United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934

If you have purchased QuantumScape securities and / or would like to discuss your legal rights and options, please visit the QuantumScape Shareholder Class Action or contact Matthew E Guarnero toll free at (877) 779-1414 or MGuarnero @ bernliebcom

The complaint alleges that throughout the class action period, the defendants made materially false and / or misleading statements, and did not disclose material adverse facts regarding the business, operations and prospects of the society Specifically, the defendants did not disclose to investors that: (i) the company’s alleged success with its solid-state battery power, lifespan and energy density was significantly overestimated ; (ii) the company is unlikely to be able to adapt its technology to the multi-layered cell needed to power electric vehicles; and (iii) as a result of the foregoing, the defendants’ positive statements about the business, operations and prospects of the company were materially misleading and / or lacked reasonable basis

On January 4, 2021, an article was published on Seeking Alpha This article highlighted a number of risks associated with QuantumScape solid-state batteries These risks make QuantumScape batteries “totally unacceptable for electric field vehicles real-world “The article clarified that QuantumScape’s battery power meant it” would only last 260 cycles or about 75,000 miles of aggressive driving “

Hearing this news, QuantumScape’s stock price fell $ 3449 or around 4084% to close at $ 4996 per share on January 4, 2021

If you wish to become the principal applicant, you must move the Court no later than March 8, 2021 A lead plaintiff is a representative party acting on behalf of the other class members in directing the dispute Your ability to participate in any collection does not require you to act as the lead plaintiff If you choose to do nothing, you can stay an absent group member

If you have purchased QuantumScape securities and / or wish to discuss your legal rights and options, please visit https: // wwwBernliebcom / cases / quantumscapecorporation-qs-shareholder-class-action-lawsuit-stock-fraud-352 / apply / or contact Matthew E Guarnero toll free at (877) 779-1414 or MGuarnero @ bernliebcom

Since 1993, Bernstein Liebhard LLP has collected more than $ 3.5 billion for his clients In addition to representing individual investors, the firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and sue on their behalf Due to its success in hundreds of lawsuits and class actions, the firm has been named thirteen times on the National Law Journal’s “Hot List” and listed in The Legal 500 for ten consecutive years.

LAWYER ADVERTISEMENT © 2021 Bernstein Liebhard LLP The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414 The lawyer responsible for this advertisement Advertising in the State of Connecticut is Michael S Bigin Past results do not guarantee or predict a similar result with respect to any future matter

A massive project changed the face of America in 1935 But now Biden is ready to continue that plan 85 years later, creating sweeping changes across the country

Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) reduced its positions in Apple Inc (NASDAQ: AAPL) and accumulated shares of pharmaceutical, telecom and oil companies during the last quarter, according to filings with the US Securities and Exchange Commission What happened: The company led by Warren Buffett lost its 6% stake in Apple to 887 million shares in the quarter, but at the same time increased its investments in AbbVie Inc (NYSE: ABBV) by 20%, Bristol-Myers Squibb Company (NYSE: BMY) by 11% and Merck & Co, Inc (NYSE: MRK) by 28% The conglomerate increased its 136% exposure to T-Mobile US, Inc (NASDAQ: TMUS) to 52 million shares and also added 1,467 million shares of Verizon Communications Inc (NYSE: VZ) See also: Warren Buffett’s Berkshire bet on these four drugmakers amid the Berkshire pandemic took a new stake of 485 million ac tions Chevron Corporation (NYSE: CVX) and 34% increase in its investment in The Kroger Co (NYSE: KR) Other changes include a 59% reduction in exposure to Wells Fargo & Co (NYSE: WFC) and a 28% reduction in Suncor Energy Inc’s (NYSE: SU) stake Why this matters: Apple is still the biggest investment in Berkshire’s portfolio, since the last 13F deposit, and the investment is worth around $ 120 billion in dollars See Also: Warren Buffett Called Bitcoin ‘Rat Poison’ – It Now Ends On Berkshire Hathaway Valuation Apple shares closed almost 16% lower to $ 13319 on Tuesday and fell another 041% In the after-hours session Tuesday, in the after-hours session, shares of AbbVie rose 042% to $ 104.64 Bristol-Myers stock rose 034% to $ 59.60 Shares of T- Mobile rose 086% to $ 123 05 Verizon shares soared 305% to 55 $ 80 after-hours trading, while Chevron shares rose 254% to $ 95.50 Wells Fargo shares were down 011% in the afternoon Shares of Kroger and Suncor were largely unchanged Stock Price: Berkshire Hathaway’s Class A shares closed 123% higher at $ 369,333 The company’s Class B shares closed 115% higher at $ 245 28 and fell 011% in the after-hours session Photo by Fortune Live Media on Flickr Learn More About BenzingaClick Here For BenzingaTikTok Option Transactions In Public Negotiations On NYSE: Chinese MediaWhy Apple Is Getting More Serious In Car Making? Smartphone “ transport ” dwarf market, according to Munster © 2021 Benzingacom Benzinga does not provide investment advice All rights reserved

What are the fastest growing stocks to watch in 2021? Here’s a list with DocuSign, Square, Daqo and four other stocks predicting growth of up to 128%

Renowned ETF investor and manager Cathie Wood joined Scott Wapner and Bob Pisani on CNBC’s ‘halftime report’ on Wednesday to share opinions on some holdings in its Wood On Tesla funds: Wood was a notable bull on Tesla Inc (NASDAQ: TSLA) and it remains the largest stake in the signature ETF Ark Innovation (NYSE: ARKK) “Our confidence in Tesla has grown,” said Wood The fund manager said no one is modeling Tesla’s carpooling potential when forecasting revenue and price targets Ridesharing Could Be More Profitable For Tesla Than Electric Vehicles Related Link: 7 Stocks That Fit Cathie Wood’s Big Ideas 2021, Could Be Added To ETFs Ark Wood On Bitcoin: Wood Has Been Bullish On Bitcoin Recently Hit On The Rise Of The valuation that could be seen if each S&P 500 company allocated 1% of cash to cryptocurrency “We now have people who really understand,” Wood said of Gary Gensler, the new US SEC Chairman Gensler taught a course on blockchain and Bitcoin at MIT and includes technology and valuation, Wood added The Grayscale Bitcoin Trust (OTC: GBTC) is a popular option for US investors to gain exposure to Bitcoin as no ETF is currently available Wood said the likelihood of a Bitcoin ETF increases with new administration including cryptocurrency Fund manager praises companies like Tesla and Square Inc (NYSE: SQ) who are “on the safe side of change” by adding Bitcoin and diversifying their cash Wood On Telemedicine: Teladoc Health (NYSE: TDOC) is one of the biggest stocks in ETF Ark The telemedicine company is owned in the Ark Innovation ETF, the Ark Genomic Internet ETF (BATS: ARKG) and the Ark Next Generation Internet ETF (NYSE: ARKW) “We had a great opportunity to buy Teladoc when the shares household have stabilized, “said Wood Although the stock rose 40% in 2021, Wood remains optimistic and believes the company has been affected by public sentiment of the Livongo acquisition.” It’s a nice acquisition for Teladoc, ”said Wood, adding that the two companies will jointly create a data center Wood on SPAC: Fund manager Ark recently added several PSPCs to the portfolio, some of which have completed mergers and others like Experience Investment (NASDAQ: EXPC) which are in the process of being merged Wood named DraftKings Inc (NASDAQ: DKNG), Skillz (NYSE: SKLZ) and Butterfly Network Inc (NYSE: BFLY) as former PSPCs held by Ark funds “We’re investing in it,” Wood said of PSPCs “We are very careful” Wood said the fund was selective and didn’t like the incentive structure of some PSPCs The fund manager noted that PSPCs remain a way for public markets to invest in some growth earlier than the traditional IPO route Space ETF: Wood To Launch Space ETF Soon Under Ark Fund Umbrella Due to a quiet period with the SEC, Wood was unable to discuss specific space stocks, but was bullish on the industry as a whole. called space exploration the bright side of change “We see SpaceX, Blue Origin pushing the boundaries,” Wood said of private companies She highlighted the work Elon Musk, Jeff Bezos and Richard Branson have done in the space industry Rocket launch costs drop dramatically, which could lead to strong industry growth, according to Wood See more from BenzingaClick here for options trades from BenzingaQuantumScape could have groundbreaking EV battery technology: WedbushOrigin Materials Lands SPAC Deal: what investors should know about Pepsi-, Danone-, Nestle-Backed Company © 2021 Benzingacom Benzinga does not provide investment advice All rights reserved

Investors are always looking for the best opportunities in the stock market One of the go-to places for outsized returns is the biotech sector These companies, like investors, are also looking; for finding medical solutions where it’s needed When hitting medical gold, the rewards can be phenomenal for early investors who quickly recognized the potential However, where space offers a nice reward, it comes with many risks.If a company does not meet the requirements to bring a treatment to market, the implications can be brutal for the headline and, therefore, for the pockets of investors. investors After clinical trials are complete, the last hurdle to drug approval is meeting with regulators Prescription Drug User Fee Act (PDUFA) dates – the deadline for review of new drugs by the FDA – determine whether or not a treatment is suitable and a yes or no can act as a major catalyst to send actions soaring or falling With that in mind, we opened up the TipRanks database to get a look at three actions biotechnology awaiting the next PDUFA dates All are currently rated Buy, with Street analysts predicting strong gains in the coming year Cormedix (CRMD) We will start with Cormedix, a biopharmaceutical company specializing in infectious and inflammatory diseases, whose PDUFA date is approaching. not The only focus of Cormedix at the moment is Defencath, a synthetic broad-spectrum antimicrobial and antifungal drug, and on February 28, the FDA will decide whether to cut mustard The company developed the treatment to counter infections in the bloodstream related to it catheters (“CRBSI”) in end stage renal disease patients receiving hemodialysis via a central venous catheter Defencath is already on the market in Europe and other regions under the brand name Neutrolin B Riley analyst Andrew D ‘Silva thinks recent actions by the FDA bode well for the drug’s chances of approval. “CRMD has been given priority review re for the candidate, which reduced the submission review time by the FDA from ~ 10 months to ~ 6 months, and the FDA subsequently determined that an AdCom meeting was not required As a result, we increase the likelihood of success of an FDA approval from 70% to 85%, which is in line with typical approval rates seen for applicants once an NDA / BLA has been submitted, ”commented D’Silva Given the results of the candidate’s Phase 3 study, in which the treatment showed a statistically significant 71% decrease in CRBSI in patients on hemodialysis compared to heparin, D’Silva believes that Defencath could save costs. to the health system about $ 1 billion per year This without even taking into account the “benefits of reducing the use of antibiotics, improving the quality of life, reducing mortality or a willingness to pay (WTP) per quality-adjusted life year (QALY) gained “D’Silva’s calculations lead him to believe that Cormedix’s TAM (Total Addressable Market) for hemodialysis is around of $ 1 to $ 7 billion Consistent with his bullish approach, D’Silva rates CRMD as outperforming (ie Buy) with a price target of $ 25 If his thesis comes to fruition, a potential gain of 75% could be in the cards (To look at the ‘D’Silva history, click here) In the enense mble, CRMD stocks get unanimous opinion, 4 buys supporting the stock’s Strong Buy consensus rating Stocks sell for $ 14.30, and the average price target of $ 22 suggests upside potential of around 54% at From that level (See CRMD stock market analysis on TipRanks) Kiniksa Pharmaceuticals (KNSA) Next, we have Kiniksa Pharmaceuticals, and unlike Cormedix, the company has a diverse pipeline of drugs in different stages of progress – all focused on weakening disease with significant unmet medical need Kiniksa’s next catalyst is the PDUFA date of March 21 for rilonacept, for the treatment of recurrent pericarditis (RP), an agonizing and debilitating autoinflammatory cardiovascular disease The FDA granted both orphan drug and breakthrough therapy status for the treatment that showed positive results in the phase 3 study With approximately 40,000 RP patients in the US either seeking medical treatment or undergoing treatment, Kiniksa is focused on bringing a treatment to market that not only treats the symptoms of a pericarditis recurrence, but also reduces the likelihood of future recurrences Among fans, Wedbush analyst David Nierengarten, who believes the company has the right approach “We think the marketing message is strong and simple: in addition to the ‘impressive high-level efficacy, major secondary endpoints of patient-reported quality of life and gradual reduction of core drugs support its use, ”said 5-star analyst The analyst added: “Overall, we view KNSA’s rational marketing strategy for rilo as encouraging and we expect the program to be well received by cardiologists who treat a disproportionate number of patients with pericarditis. recurrent and by patients given the early onset convincing benefitsBased on all of the above, Nierengarten awards KNSA an outperformance (ie Buy) with a price target of $ 35 This target puts the upside potential at 55% (To view Nierengarten’s history, click here) Other analysts share a similar enthusiasm with Nierengarten regarding KNSA Given that 3 buy ratings have been given in the past three months with respect to no take or sell, the consensus is unanimous: l ‘Stock is a’ strong buy ‘Meanwhile, it’s $ 31 The average price target of 67 places the potential year over year gain at ~ 40% (See KNSA market analysis on TipRanks) Aveo Pharmaceuticals (AVEO ) In hopes of providing better patient outcomes, AVEO Pharmaceuticals is advancing targeted drugs for oncology and other unmet medical needs The company has various drugs in development, but the focus is currently on on the next decision of the FDA for Tivozanib, the company’s third- and fourth-line treatment for advanced renal cell carcinoma (CRC) The drug is already approved to treat adult patients with advanced renal cell carcinoma (CRC) in other regions, particularly in the European Union, Norway, New Zealand and Iceland. The PDUFA date is set for March 31 and following positive data from the late stage study, Baird analyst Michael Ulz believes a positive result is in the cards “Tivozanib was shown to significantly increase the quality-adjusted time without symptoms or toxicity (Q-TWiST) compared to sorafenib (1504 versus 1278 months; p = 00493), demonstrating a differentiated tolerability profile based on a measure of the quality of life of tivozanib, despite similar overall survival (OS) results We continue to see potential for approval based on the TIVO-3 study and we expect investor attention to remain on the next PDUFA date (March 31), which we see as the next key enabler, ”said Ulz To this end, Ulz evaluates AVEO a purchase with a target price of $ 17 The implication for investors? 106% rise (To see Ulz track record, click here) It has been relatively calm with regard to other analysts’ business Over the past three months, only 2 analysts have issued notes However, as they were both buying, the word on the street is AVEO is a moderate buy Based on the $ 13 average price target of 50, stocks could climb about 64% over the next twelve months (See AVEO Stock Analysis on TipRanks) To get great ideas for biotech stocks traded at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that brings together all the information about TipRanks stocks Disclaimer: The opinions expressed in this article are those of the featured analysts only The content is intended to be used for informational purposes only It is very important to do your own analysis before making any investment

Palantir stock fell as 2021 revenue forecast slightly below expectations Palantir stock also faces a test on Thursday when its lock-in period expires on Thursday. IPO

Warren Buffett goes looking for equities in Q4, new file finds

Thomas Peterffy, Founder and Chairman of Interactive Brokers Group Inc, explained on Wednesday the dire situation the market found itself in in late January, as individual investors on social media platforms rallied to send a handful of strongly shorted actions considerably above

Congress burns rubber to get bill to President Biden in a race against time

Today we take a look at two small-cap biotech companies whose stocks have hit a rut Each company has experienced a recent clinical setback that caused the stock price to fall, erasing previous gains and sending it back to low levels Setbacks like this are not uncommon in the biotech industry and highlight the risk and speculative nature of the industry So what should investors do when a stock crashes? Is it a question of bad fundamentals? And has the share price still bottomed out? This is where the Wall Street pros come in Noting that each is set to start again on an upward trajectory, some 5-star analysts see an attractive entry point for both Using TipRanks’ database, we discovered that these two tickers have obtained moderate to strong buy consensus ratings from the analyst community and have strong upside potential Cortexyme, Inc (CRTX) The first shot down name we’re looking for is Cortexyme, a clinical-stage biopharmaceutical company focused on degenerative diseases, specifically Alzheimer’s disease. The company’s lead candidate is COR388, also known as atuzaginstat Atuzaginstat is currently being investigated as part of the GAIN trial, a study of its effectiveness against Alzheimer’s disease The trial is fully recruited, with 643 patients, and the company is moving towards an open-label enrollment (OLE) section of the phase 2/3 study In a routine regulatory update, Cortexyme announced that the OLE phase will be discontinued , although the primary GAIN study is ongoing, with results to be released in Q4 2021 The announcement of the partial discontinuation caused a 35% decrease in the course of action The partial suspension was caused by adverse events in the liver during the atuzaginstat trial The hepatic symptoms were reversible and were not shown no long-term lasting effects The FDA reviewed these files and, in collaboration with Cortexyme, the decision was made to hold the OLE while pursuing GAIN This decision allows the main focus of the program to continue, while developing a new protocol for OLE The aim of the OLE is to test the long-term efficacy and tolerability of the drug In a review of Cortexyme after the announcement, HC Wainwright 5-star analyst Andrew Fein, noted: “Cortexyme’s announcement of a partial clinical suspension of the OLE study of atuzaginstat is disappointing, but the reversible nature of the liver toxicity may provide a silver lining for Cortexyme. We believe that further the pivotal test suggested era that the drug-induced liver injury might not be severe enough to interrupt the program “As for the short term, adds Fein,” The continuation of the GAIN trial is encouraging despite the partial maintenance of OLE. suggests FDA plans to wait for additional pivotal trial data before reaching a conclusion Management shared that nearly one-third of GAIN patients had completed the study and exceeded the 12-week deadline, suggesting they are out of risk. “To this end, Fein is evaluating CRTX a Buy, and its goal price of $ 76 indicates confidence in 147% growth potential (To see Fein’s track record, click here) Overall, Cortexyme has an analyst consensus moderate buy rating, with 6 recent reviews ranging from 4 to 1 to 1, buy-hold-sell stock is $ 83 60 The average price target suggests that Wall Street sees high potential, in the range of ~ 170% upward from the $ 30 trading price 74 (See CRTX stock market analysis on TipRanks) Immunovant ( IMVT) Next is Immunovant, a clinical-stage biopharmaceutical research company focused on developing treatments for patients with autoimmune diseases, a class of diseases in which the immune system attacks the patient’s own body The leading drug candidate company, IMVT-1401, is currently in trials for the treatment of thyroid eye disease, myasthenia gravis and warm autoimmune hemolytic anemia The drug described as “a new monoclonal antibody fully human anti-FcRn, ”given by subcutaneous injection On February 2, Immunovant’s action plunged by 42%, and it has been declining since The trigger was an announcement by the company that IMVT- 1401 saw its Phase 2b clinical trial for thyroid disease suspended temporarily due to patients experiencing dangerous increases in their LDL levels LDL is the potentially harmful form of cholesterol, which has been linked to cardiovascular disease Despite the clinical setback, 5-star Stiffel analyst Derek Archila reiterated a buy rating on IMVT stocks, along with a price target $ 28 This figure suggests a potential for an increase of 52% from current levels (To view Archila’s history, click here) “Interestingly, increases were only seen in PDD patients, and our review literature suggests a few things: (1) it is likely that this is specific to TED given the biology – see below for details, but we do not believe that similar increases in LDL will be seen in others indications outside TED; and (2) other anti-thyroid therapies used in Graves / TED also see similar increases in LDL, which end up being transient We believe that IMVT-1401, on the inside, mimics this mechanism, ”noted the analyst Archila summed up: “We’ll need more data from the company to confirm we don’t think this program is dead.” Overall, Strong Buy analysts’ consensus view on IMVT suggests that Wall Street is generally dead. ‘agrees with Archila’s assessment This rating is taken from 8 recent reviews, including 7 purchases and only one wait.The average price target here is $ 4038, which implies a ~ 121% rise for the next 12 months (See IMVT market analysis on TipRanks) To get great ideas for stocks traded at attractive valuations, visit Best Stocks to Buy from TipRanks, a newly launched tool that brings together all information about TipRanks stocks Disclaimer: Opinions expressed in this article are only those Featured Analysts Content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment

Massive new budget spending under Democrats supports long-term gold case, but faster Fed tightening could weigh on gold for a while

Each week, Benzinga conducts a survey to gather opinions on the topics that are most excited, interested or in which traders think about when managing and building their personal portfolios This week, we asked more than 1,000 merchants and investors the following question about whether 5G wireless giants AT&T Inc (NYSE: T) or Verizon Communications Inc (NYSE: VZ) should acquire Nokia (NYSE: NOK) in 2021: AT&T should buy Nokia Verizon should buy Nokia Nor should AT&T buy Nokia As AT&T and Verizon are the largest wireless carriers in the country, they are expected to be the most competitive companies for the largest 5G cellular technology market share in coming years Verizon is the largest US mobile operator, serving approximately 89 million postpaid customers and 4 million prepaid phone customers AT&T is the second largest US operator in mobile telephony, with 63 million postpaid customers and 16 million prepaid telephony customers Verizon Nokia: Regarding active business relationships s, Verizon partnered with Nokia in October to bring private 5G capabilities to businesses across Europe and the Asia-Pacific territories.Private 5G will enable organizations to deliver critical and real-time capabilities and l Verizon’s continued investment in 5G and network-as-a-service strategy, companies say See also: How to buy Verizon shares AT&T Nokia: Like with Verizon, it’s no secret AT&T and Nokia have an active partnership in place to take advantage of their 5G technologies The agreement between AT&T and Nokia shows how AT&T enterprise customers can connect and manage a multitude of Internet of Things (IoT) devices on their networks, taking advantage of the capabilities of Nokia WING, including increased performance and flexibility, and lower latency The current AT&T-Nokia partnership also highlights how, as IoT networks move to 5G and Nokia WING also supports 5G network slicing, AT&T will be able to partition its 5G network into multiple networks capable of delivering capacity. specific to its IoT customers and support various use cases According to the survey: While the 5G partnership has caught the attention of our respondents, only 28% believe that Verizon should go ahead and complete an M&A with Nokia by the end of the year About 30% of respondents think an AT&T-Nokia makes sense in 2021 Meanwhile, 42% of respondents told us that AT&T and Verizon should not attempt a deal M&A in 2021 Many respondents simply believe that Nokia has an opportunity to reorganize, or that Nokia simply has too much debt for AT&T and Verizon to bother to take Nokia’s long-term debt stands at $ 5 time of publication See more from BenzingaClick here for Benzinga options trades Here’s why MicroVision, Verizon and Slack are moving We asked 1000 readers if Tesla or Nio makes EV cooler © 2021 Benzingacom Benzinga doesn’t provide investment advice All rights are reserved

Jeff Bezos is the richest person in the world again, taking his title back from Elon Musk, who has seen his wealth slow with the recent drop in Tesla shares

There is no one-size-fits-all Identify what you will need in retirement and your schedule till date, and figure out what to expect from your 401 (k) from there

(Bloomberg) – What started as a power problem for a handful of US states is shocking the global oil market Over 4 million barrels per day of production – nearly 40% of nation’s crude production – now offline, traders and executives say One of the world’s largest oil refining centers has seen production decline dramatically The waterways that help US oil flow to the rest of the world were disrupted for much of the week “The market underestimates the amount of oil production lost in Texas due to bad weather,” said Ben Luckock, co-head of oil trading at commodities giant Trafigura GroupBrent surged to less than 25 cents from $ 65 a barrel on Wednesday, a level not seen since last January Ten months ago, it fell below $ 16 due to a demand shock caused by Covid-19 In the past, the weather-related disruption would have been largely a US problem It is now unmistakably global Crude markets in Europe recover as traders replace lost U exports OPEC and its allies must decide how many Still they will keep millions of barrels of their supply off the market Estimates of the duration of outages have grown steadily in recent days as analysts attempt to determine how long infrastructure thaws, especially in areas where freezing temperatures have occurred. is not the norm Higher estimates Initially, traders and consultants expected success for US production that would last between two and three days Mainten ant, it seems unlikely that things will start to recover much before the weekend This means more barrels are withdrawn from the global market Citigroup Inc has said it expects a production loss of 16 million barrels until early March, but some traders’ estimates are now almost double Vast swathes of production in the Permian – the heart of US shale production – have been shut down The result has been an increase in the value of barrels of crude in other parts of the world North Sea traders have made frantic bids for the region’s cargoes this week as replacements are sought for US crude exports As supplies in Europe have grown more expensive, Asian buyers have bought Middle Eastern shipments at higher premiums And although global crude futures are at their highest level since is more than a year, they have not increased yet because the loss of refining capacity is just as serious The country’s largest plant has closed and at least 3 million barrels a day of processing has been taken offline Traders rush to send millions of barrels of diesel across the Atlantic to the US, a godsend Potential for the oppressed refining industry in Europe Gasoline machine “The Gulf Coast is a gasoline machine and sends products across the US as well as international markets,” said Kitt Haines, analyst at Energy Aspects. short period at least, it could help European refining “The result will mean a mixed picture for US inventories in the coming weeks As gasoline production has been hit by the wave of refinery outages, there are also many fewer drivers on the roads than usual Stocks of heating fuels like propane and diesel – for which demand was already skyrocketing ahead of this week’s weather conditions – are set to drop sharply – all of this leaves Saudi Arabia and its allies in the Organization of Exporting Countries oil company closely monitoring Texas weather forecast April decision The group has yet to halt production plans for April, but OPEC’s largest producer surprised oil markets earlier in the year by cutting a million additional barrels per day in February and March This leaves reserve capacity on the sidelines at a time when the market calls for additional barrels “The market is becoming a wild animal for OPEC to control,” Gary said Ross, a seasoned oil consultant turned hedge fund manager at Black Gold Investors LLC “The weather has an incredible impact on global supply and demand” A thaw is coming, however on Friday temperatures in Midland – the de facto capital of shale production – will reach 45 Fahrenheit (7 degrees Celsius) This will drop to 56 Fahrenheit on Saturday, allowing crude production to restart On Monday, Midland hit -2 degrees Fahrenheit, its lowest temperature in more than 30 years. For now, the big unknown remains how long it will take production – and rest of the region’s oil infrastructure – to fully recover “The proof of the last great Permian freeze is that it can come back very quickly,” said Paul Horsnell, head of commodities research at Standard Chartered Plc “But refineries are more likely to be prone to prolonged damage” For more articles like this please visit us at bloombergSubscribe now to stay ahead with the most popular source of business news reliable © 2021 Bloomberg LP

Shares of Apple Inc fell to a one-month low on Wednesday and fell below the chart’s two key levels in the process, after the tech giant’s two largest shareholders revealed they had reduced their stakes

After the coronavirus dented growth prospects last year, Albemarle and peers like SQM now expect to capitalize on the growing demand for the lithium metal battery, essential for electric vehicles that have become overwhelmingly popular amid climate change concerns Albemarle said earlier he plans to double production at his Silver Peak, Nevada lithium plant as part of a plan to increase market supply boom in electric vehicles, while Chilean miner SQM announced its current intention to boost its production of lithium carbonate and lithium hydroxide in the second half of 2021 remained on track.However, Albemarle warned that it expects prices to drop slightly and adjusted profit in the order of $ 3$ 25 to $ 3 65 per share for 2021

Tilray beat some fourth quarter expectations and became the rare cannabis company to meet profitability targets

Twilio released fourth quarter results that exceeded both its own forecast and Street Son estimates, its stock surged in response

Qs Shares

Ebene News – United States – QS SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of Deadline to File Main Plaintiff’s Motion in Class Action securities against QuantumScape Corporation

Source: https://finance.yahoo.com/news/qs-shareholder-deadline-bernstein-liebhard-220700394.html